It has been demonstrated that a CD16‐targeting and CD33‐targeting BiKE is efficacious against MDS and AML blasts in AML, especially when used in conjunction with an inhibitor of the disintegrin and MP domain‐containing protein 17 (ADAM17), which maximizes ADCC activation.239. The gene discussed is CD33; the disease is acute myeloid leukemia.